KEAP1 and chronic obstructive pulmonary disease: Moreover, three in vivo studies showed that AST administration inhibited the development of chronic obstructive pulmonary disease (COPD) and acute lung injury through activation of Nrf2 and, accordingly, promoted HO-1 and inhibited Keap1 [85,94].